A Population Pharmacokinetic Model to Assess the Cytochrome P450 2B6 Metabolic Probe Bupropion and Hydroxybupropion in Vitamin D‐Insufficient and ‐Replete Patients With Kidney Disease
Journal of Clinical Pharmacy and Therapeutics · 2026-01 · 2026 (1)
DOI: 10.1155/jcpt/3265655 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Pharmacy and Therapeutics, online erschienen am 08.03.2026. Verfasst von Avisek Ghimire und 10 weiteren Autor:innen. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institutes of Health, University of Colorado, University of Pittsburgh.
Abstract (Originalsprache)
Objective
The aim of this study was to use bupropion as a cytochrome P450 (CYP) 2B6 probe to determine CYP2B6 function by using a population pharmacokinetic approach of parent bupropion and metabolite hydroxybupropion to explore the impacts of chronic kidney disease (CKD) and vitamin D status in patients and control subjects.
Methods
Plasma concentration data from 19 subjects after administration of 150 mg of sustained‐release bupropion were used in pharmacokinetic modeling. Blood samples were collected pre‐dose and serially post‐dose and analyzed by LC‐MS/MS. Population pharmacokinetic analysis was conducted using nonlinear mixed‐effect modeling (Phoenix NLME v8.6.1.6, Certara Inc.). A separate post hoc analysis evaluated the formation clearance of hydroxybupropion as an assessment of CYP 2B6 functional activity.
Results
The final model was composed of 2 compartments with first‐order formation and elimination for bupropion and hydroxybupropion. A multiplicative error model explained residual variability. Covariates tested in the model, including vitamin D baseline concentrations and CKD, did not have a significant impact on the pharmacokinetics of bupropion and hydroxybupropion. Model validation was performed using visual predictive check. A trend toward increased formation clearance was observed within the CKD group (2.21 L/h vs. 2.65 L/h, p = 0.39) and a slight reduction in the control group (2.96 L/h vs. 2.66 L/h, p = 0.85) with vitamin D repletion vs. insufficiency.
Conclusion
The study contributes to the understanding of CYP 2B6 function in CKD and exhibited increased CYP2B6 function in CKD subjects with vitamin D repletion.
Förderung
- National Institutes of Health
- University of Colorado
- University of Pittsburgh
Zitieren
APA
Ghimire, A., Tuey, S. M., Prebehalla, L., Atilano-Roque, A., Roda, G., Thompson, L. E., Chonchol, M. B., Shah, N., Wempe, M. F., Nolin, T. D., & Joy, M. S. (2026). A Population Pharmacokinetic Model to Assess the Cytochrome P450 2B6 Metabolic Probe Bupropion and Hydroxybupropion in Vitamin D‐Insufficient and ‐Replete Patients With Kidney Disease. Journal of Clinical Pharmacy and Therapeutics, 2026(1). https://doi.org/10.1155/jcpt/3265655
Vancouver
Ghimire A, Tuey SM, Prebehalla L, Atilano-Roque A, Roda G, Thompson LE, et al. A Population Pharmacokinetic Model to Assess the Cytochrome P450 2B6 Metabolic Probe Bupropion and Hydroxybupropion in Vitamin D‐Insufficient and ‐Replete Patients With Kidney Disease. Journal of Clinical Pharmacy and Therapeutics. 2026;2026(1). doi:10.1155/jcpt/3265655
BibTeX
@article{Ghimire2026,
author = {Ghimire, Avisek and Tuey, Stacey M. and Prebehalla, Linda and Atilano-Roque, Amandla and Roda, Gavriel and Thompson, Lauren E. and Chonchol, Michel B. and Shah, Nirav and Wempe, Michael F. and Nolin, Thomas D. and Joy, Melanie S.},
title = {A Population Pharmacokinetic Model to Assess the Cytochrome P450 2B6 Metabolic Probe Bupropion and Hydroxybupropion in Vitamin D‐Insufficient and ‐Replete Patients With Kidney Disease},
journal = {Journal of Clinical Pharmacy and Therapeutics},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/jcpt/3265655}
}
EUVIMED